ReviewPharmacoEconomics1996
Evaluating the impact of influenza vaccination. A North American perspective.
Review in PharmacoEconomics, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Interventions to increase influenza vaccination rates of those 60 years and older in the community.The Cochrane database of systematic reviews · 2018Pooled it
- Interventions to increase influenza vaccination rates of those 60 years and older in the community.The Cochrane database of systematic reviews · 2014Pooled it
- Immune response to influenza vaccination in an elderly population.Journal of clinical immunology · 2003Article
- A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK.PharmacoEconomics · 2002Article
- Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.Drugs & aging · 2000Review
- Economic evaluations of influenza vaccination in healthy working-age adults. Employer and society perspective.PharmacoEconomics · 2000Article
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies in the US and Canada have shown that influenza vaccination prevents approximately 30 to 50% of all pneumonia and influenza hospitalisations and deaths that occur among elderly persons during 3-month influenza outbreak periods. These population-based studies have used retrospective methods and large computerised administrative databases. In addition, earlier cost-effectiveness studies have been supplemented by recent research from prepaid health plans showing that influenza vaccination can be cost saving. The use of influenza vaccine increased in the US and Canada throughout the 1980s and early 1990s, despite different methods for providing reimbursement for vaccination. The North American experience regarding the clinical effectiveness, cost effectiveness and epidemiology of influenza vaccination may provide European scientists and health officials with useful although sometimes limited insight into their own efforts to understand and improve influenza vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.